Side effect of Gilenya
Progressive multifocal leukoencephalopathy has been added as an adverse event of unknown frequency to the summary of product characteristics for Gilenya (fingolimod; Novartis).
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200825
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com